Executive perspectives: Sir Andrew Dillon (part 2)
Paul Tunnah interviews Sir Andrew Dillon
The National Institute for Health and Clinical Excellence
(Continued from “Executive perspectives: Sir Andrew Dillon (part 1)”
We recently spoke with Sir Andrew Dillon, Chief Executive of the UK’s National Institute for Health and Clinical Excellence (NICE), which plays a critical role in managing healthcare delivery pathways in the UK and is now well known globally. During the first part of this two part interview, Sir Andrew shared his thoughts on how NICE has developed over the years and the kind of relationship it has with pharma.
Here, in the second part of this piece, we move on to discuss some more specific challenges around the use of ‘risk-share’ schemes for the managed introduction of new medical interventions and how implementation of NICE guidelines can be improved. Furthermore, Sir Andrew responds to the challenge from pharma of potentially dissuading innovation through the evidence required for health technology appraisal and how NICE is becoming recognised as a valuable player globally in advising on efficient healthcare solutions.
To watch the second part of this interview, please click on the play button below.
0:15 – The role of NICE in assessing ‘risk-share’ schemes.
1:37 – How implementation of NICE guidelines can be improved.
4:03 – Could the increasing evidence base NICE requires dissuade innovation?
6:10 – The part NICE has to play in providing its expertise globally.
Subscribe to pharmaphorum on YouTube to be the first to hear about new videos – http://www.youtube.com/pharmaphorum.
About the interviewee:
Sir Andrew Dillon joined the NHS in 1975 and has held a number of senior management positions, including General Manager of the Royal Free Hospital and Chief Executive of St George’s Healthcare NHS Trust. He joined the National Institute for Health and Clinical Excellence (NICE) as its founding Chief Executive in 1999.
Operating within the UK, NICE is the independent organisation responsible for providing national guidance and standards on the promotion of good health and the prevention and treatment of ill health. Its work focusses on providing guidance around the three core areas of public health, health technologies (including recommendation on the cost-effectiveness of new medicines) and clinical practice. In addition, NICE produces key quality standards for patient care and supports development of the quality and outcomes framework (QOF) indicators. It has become recognised globally as a model for helping health professionals deliver the best evidence-driven patient care.
For more information about NICE please visit www.nice.org.uk.
What role is there for NICE as a global advisor on healthcare delivery?